RIPK3 and cancer: A necroptosis sensitivity screening revealed that 780 (83%) cell lines among a panel of 941 human cancer cell lines from 28 tissues are fully resistant to necroptosis due to the loss of RIPK3 expression that mediated by oncogenes BRAF and AXL [110].